Zydus Lifesciences arm secures USFDA nod for tardive dyskinesia drug Valbenazine

Published On 2022-10-17 07:00 GMT   |   Update On 2022-10-17 07:24 GMT
Advertisement

Ahmedabad: Zydus Lifesciences Limited's (formerly known as Cadila Healthcare Limited) subsidiary Zydus Worldwide DMCC has received tentative approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules USP 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza).

Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia.

Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips, and tongue, such as grimacing, sticking out the tongue, and smacking the lips. Some affected people also experience involuntary movement of the extremities or difficulty breathing.

Advertisement

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Valbenazine Capsules had annual sales of USD 781mn in the United States, according to IQVIA data (IQVIA MAT Aug 2022). The group now has 327 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Healthcare gets CDSCO panel nod to manufacture, market Indacaterol, Budesonide Inhaler

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs. Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.

Read also: Zydus Lifesciences US arm bags USFDA nod for Brivaracetam Tablets to treat partial-onset seizures

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News